Sachin Hansalia, MD
Critical Care Medicine · Charlotte, NCNPI 1023025814
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $971 and has fallen 50.3% since, to $483 in 2025.
Across 30 payments — averaging $63.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$425
- Boehringer Ingelheim$308
- GSK$165
- Merck$159
- La Jolla Pharmaceutical Company$125
- Sanofi$122
- plus $602 from 9 others
What the payments were for
- Food & beverage$1,87098%
- Education$362%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 5 | $425 |
| Boehringer Ingelheim | 6 | $308 |
| GSK | 3 | $165 |
| Merck | 3 | $159 |
| La Jolla Pharmaceutical Company | 1 | $125 |
| Sanofi | 1 | $122 |
| United Therapeutics Corporation | 2 | $120 |
| Genentech USA, Inc. | 1 | $119 |
| Actelion Pharmaceuticals US, Inc. | 2 | $114 |
| Johnson & Johnson | 1 | $109 |
| Inspire Medical Systems, Inc. | 1 | $59 |
| Insmed, Inc. | 1 | $28 |
| Amgen | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Melinta Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,906 in reported general payments places this provider in the 80th percentile of 190 critical care medicine providers in North Carolina.
See all critical care medicine providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 24 | $587,576 |
| OpsumitMacitentan | 28 | $381,161 |
| OfevNintedanib Esylate | 19 | $249,465 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 166 | $200,011 |
| AdempasRiociguat | 12 | $169,052 |
| Fasenra PenBenralizumab | 24 | $132,793 |
| Ambrisentan | 44 | $120,707 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 51 | $60,992 |
| NucalaMepolizumab | 13 | $45,073 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $41,892 |
| EliquisApixaban | 17 | $24,548 |
| SymbicortBudesonide/Formoterol Fumarate | 61 | $23,550 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $20,764 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $18,693 |
| Spiriva RespimatTiotropium Bromide | 21 | $16,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $114 | $381,16128 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $165 | $308,254279 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $308 | $291,80475 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $425 | $84,542112 claims |
| Johnson & JohnsonXarelto | $109 | $12,85018 claims |
| MerckDulera | $159 | $6,18613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 190 critical care medicine providers in North Carolina.
Other critical care medicine in Charlotte
- Rabih BecharaCharlotte$453K
- Alan HeffnerCharlotte$326K
- John DotyCharlotte$37K
- Alfred PapaliCharlotte$10K
- Amar PanchalCharlotte$8K
- Lacey SpanglerCharlotte$3K
- Jeffrey WallsCharlotte$2K
- Luke NeilansCharlotte$2K
- Kimberly McCreaCharlotte$2K
- James RobertsCharlotte$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.